Teva Pharmaceuticals Australia Pty Ltd.
Records under this name other than the patents Teva Pharmaceuticals Australia Pty Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.
Back to Teva Pharmaceuticals Australia Pty Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,906,973 | Antibody Variants Transmigrating the Blood-Brain Barrier and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,725,052 | ANTI-PAR-2 Antibodies and Methods of Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 12,384,841 | ANTI-PAR-2 Antibodies and Methods of Use Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 12,358,980 | Compositions and Methods for Anti-Pacap Antibodies Formerly held In force · High confidence | In force | High confidence | |
| US 11,253,591 | Combination of lenalidomide and polypeptide construct, and uses thereof Lapsed on the fee record Ended Feb 22, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 22, 2026 | USPTO record |
| US 8,563,697 | Anti-IL-12/IL-23 antibodies Lapsed on the fee record Ended Oct 22, 2021 · USPTO record | Lapsed on the fee record | Ended Oct 22, 2021 | USPTO record |
| US 8,343,490 | Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent Lapsed on the fee record Ended Jan 1, 2021 · USPTO record | Lapsed on the fee record | Ended Jan 1, 2021 | USPTO record |
| US 8,273,349 | Binding member which binds to both lewis-Y and lewis-B haptens, and its use for treating cancer Lapsed on the fee record Ended Sep 25, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 25, 2020 | USPTO record |
| US 7,267,821 | Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancer Lapsed on the fee record Ended Sep 11, 2019 · USPTO record | Lapsed on the fee record | Ended Sep 11, 2019 | USPTO record |
| US 9,127,057 | Anti-IL-23 heterodimer specific antibodies Lapsed on the fee record Ended Sep 8, 2019 · USPTO record | Lapsed on the fee record | Ended Sep 8, 2019 | USPTO record |